Karin Dahlman-Wright

Karin Dahlman-Wright

Specialist | Docent
Telephone: +46852481089
Visiting address: Nobels väg 6, 17165 Solna
Postal address: GVS Gemensamt verksamhetsstöd, GVS Fakultetskansliet och internationella relationer, 171 77 Stockholm

About me

  • I am professor of molecular endocrinology and was made Vice-President of Karolinska Institutet on 1 January 2016. On 18 February that same year, the government appointed me Karolinska Institutet’s acting President, a position I relinquished on 1 August 2017 to resume my previous title. I left my position as Vice President 9 September 2019. From 2009 until August 2015 I was head of the Department of Biosciences and Nutrition, and in 2015 I was vice-dean of infrastructure.

    Between September 2013 and June 2015 I was KI Scientific Director at SciLifeLab with special responsibility for the national platforms, and was a member of SciLifeLab’s operational management. In 2001 I founded BEA, a core facility that provides advanced services in genomics and bioinformatics. From 1994 to 2000 I held the positions of line manager and project manager at Pharmacia and Upjohn. I am also active in the Strategic Research Area in Diabetes at KI.

    Commission of trust
    I am a member of the SciLifeLab Stockholm steering board and the joint steering committee for AstraZeneca/KI/ SciLifeLab collaboration. I am also a member of the reference group for the European spallation resource ESS I have acted as Chairman, vice Chairman and member of evaluation panels at the Swedish Research Council. I have evaluated research in Norway on request of the Norwegian Research Council. 2007-2008 and 2015-, I was a member of the KI-SLL infrastructure council. I have taken part in a committee on behalf of the Swedish department of justice with regard to patents in the area of biotechnology and I am appointed expert in patent cases.

    Ph.D Medical Sciences, Karolinska Institutet, 1991
    Docent Molecular Endocrinology, Karolinska Institutet, 1996


  • My research is focused on studies of estrogen signaling with specific focus on type 2 diabetes and breast cancer. We study phenotypes of mouse models with tissue selective knock-out of estrogen receptors and relate this to molecular changes such as changes in global gene expression. We use different breast cancer cell models and functional genomics technologies, such as ChIP SEQ, global gene expression analysis and proteomics, to identify signaling pathways that can include possible targets for treatment of breast cancer.


All other publications


  • Specialist, Central Administration, Karolinska Institutet, 2024-

Degrees and Education

  • Docent, Karolinska Institutet, 1996

News from KI

Events from KI